Drug programs

The drug program is a guaranteed service, i.e., financed from NFZ (National Health Fund)

Treatment under the programme uses innovative and costly active substances which are not financed under other guaranteed benefits. Treatment is carried out in selected disease entities and covers a strictly defined group of Patients. Patients are qualified for the drug programme by a physician from a centre contracted to carry out a specific programme, based on detailed programme eligibility criteria. Patients qualified for drug programmes are treated free of charge.

The description of the drug programme includes:

• Patient qualification criteria for treatment.
• Exclusion criteria from the program.
• Drug dosing schedule.
• Drug administration method.
• A list of diagnostic tests performed when qualifying a patient for the program and those necessary for treatment monitoring.

NU-MED Specialised Oncology Hospital in Tomaszów Mazowiecki implements the following drug programs:

1. DRUG PROGRAM - TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
2. DRUG PROGRAM - TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA
3. DRUG PROGRAM - TREATMENT OF SOFT TISSUE SARCOMAS
4. DRUG PROGRAM - TREATMENT OF OVARIAN CANCER, FALLOPIAN TUBE CANCER, OR PERITONEAL CANCER
5. DRUG PROGRAM - TREATMENT OF WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS
6. DRUG PROGRAM - TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
7. DRUG PROGRAM - TREATMENT OF PATIENTS WITH METASTATIC PANCREATIC ACINAR CELL CARCINOMA
8. DRUG PROGRAM - TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
9. DRUG PROGRAM - TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMAS AND OTHER B-CELL LYMPHOMAS
10. DRUG PROGRAM - TREATMENT OF RESISTANT AND RECURRENT CLASSICAL HODGKIN'S LYMPHOMA CD30+ USING NIVOLUMAB
11. DRUG PROGRAM - TREATMENT OF ADVANCED COLORECTAL CANCER
12. DRUG PROGRAM - TREATMENT OF LUNG CANCER AND PLEURAL MESOTHELIOMA
13. DRUG PROGRAM - TREATMENT OF BREAST CANCER
14. DRUG PROGRAM - TREATMENT OF KIDNEY CANCER PATIENTS
15. DRUG PROGRAM - TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
16. DRUG PROGRAM - TREATMENT OF ADVANCED ESOPHAGEAL AND GASTRIC CANCER
17. DRUG PROGRAM - TREATMENT OF SYMPTOMATIC, NON-OPERABLE, LOCALLY ADVANCED, OR METASTATIC MEDULLARY THYROID CARCINOMA
18. DRUG PROGRAM - TREATMENT OF SKIN OR MUCOSAL MELANOMA
19. DRUG PROGRAM - TREATMENT OF MERKEL CELL CARCINOMA WITH AVELUMAB
20. DRUG PROGRAM - TREATMENT OF PATIENTS WITH PROGRESSIVE, LOCALLY ADVANCED OR METASTATIC, DIFFERENTIATED (PAPILLARY/FOLLICULAR/OXYOPHILIC - HURTHLE CELL) THYROID CANCER, RESISTANT TO RADIOACTIVE IODINE TREATMENT
21. DRUG PROGRAM - TREATMENT OF PRIMARY CUTANEOUS T-CELL LYMPHOMAS - new from July 1, 2022
22. DRUG PROGRAM - TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE SKIN WITH CEMIPLIMAB
23. DRUG PROGRAM - TREATMENT OF PATIENTS WITH NEUROENDOCRINE TUMORS OF THE GASTROINTESTINAL TRACT USING RADIOPHARMACEUTICALS
24. DRUG PROGRAM - TREATMENT OF PATIENTS WITH SOLID TUMORS WITH A FUSION OF THE NEUROTROPHIN TYROSINE KINASE RECEPTOR GENE - new from September 2023
25. DRUG PROGRAM- TREATMENT OF ENDOMETRIUM CANCER PATIENTS- from January 2024